Acute Supplementation With Beta-Alanine Improves Performance in Aerobic-anaerobic Transition Zones in Endurance Athletes

University of Americas

Status: Completed

Conditions: Beta-alanine

Treatments: Dietary Supplement: beta alanine

Study type: Interventional

Funder types: Other

Identifiers

NCT05096793

04102021 (Other Identifier)

Details and patient eligibility

About

The use of beta-alanine (BA) to increase physical performance is widely documented. However, the acute effect of this amino acid on maximal tests in the aerobic-anaerobic transition zone is still uncertain. The objective of this study was to determine the acute effect of low and high-dose BA trials on maximal aerobic speed (MAS) in endurance athletes. We hypothesized that high doses of BA have a greater effect than low doses, both compared to baseline. Twelve male endurance athletes volunteered for the study. The experimental design applied was randomized cross-over, double-blind. Treatment included three 6-minute run tests (6-MRT), the first as a baseline, then randomized 6-MRT with low (30 mg·kg-1) and high (45 mg·kg-1) dose BA trials. The 6-MRTs were separated by 72 hours. The main variable of the study was the distance (m) performed in the 6-MRT. Differences between tests were established through ANOVA and Tukey's multiple comparison tests (p < 0.05).

Full description

In this original research, we determined the acute effect of low (30 mg·kg-1) and high-dose (45 mg·kg-1) BA trials on maximal aerobic speed (MAS) in endurance athletes. At the same time, we compared the effect size with of BA.

Enrollment: 12 patients

Sex: Male

Ages: 18 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• The inclusion criterion was years of training for endurance events (participants had a minimum of two years running middle-distance and long-distance events).

Exclusion criteria

• The exclusion criterion was the inability to perform the 6-minute run test

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

12 participants in 3 patient groups

Control

Experimental group

Description:

the distance in the 6-MRT compared to baseline

Treatment:

Dietary Supplement: beta alanine

Low doses

Experimental group

Description:

the distance in the 6-MRT compared to baseline

Treatment:

Dietary Supplement: beta alanine

High doses

Experimental group

Description:

the distance in the 6-MRT compared to baseline

Treatment:

Dietary Supplement: beta alanine